Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
March 3, 2008
- STATISTICS／Rate of Death due to Liver Cancer Is Third Highest in Japan
March 3, 2008
- MTX Recommended for Approval for JIA
February 25, 2008
- New System to Cover Certain Unapproved Medical Services by Insurance from April
February 25, 2008
- REGULATORY NEWS IN BRIEF
February 25, 2008
- 600 Points per Month for Managing Health of Elderly Patients
February 25, 2008
- JPMA to Study Clinical Trial Situation in Other Asian Countries
February 25, 2008
- MRI Using EOB Primovist Incorporates All Features of Conventional Methods
February 25, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 25, 2008
- Use of Standard Forms for Clinical Trial Documents
February 25, 2008
- Large-scale Databases Important for ADR Analysis
February 25, 2008
- DSP Plans to Market Lurasidone Independently in US
February 25, 2008
- Novo Nordisk Discontinues Transpulmonary Insulin Project AERx
February 25, 2008
- Dr Karasawa Will Stand for Reelection JMA President
February 25, 2008
- Taisho Initiates TOB for Biofermin
February 25, 2008
- CV Risk Lower with Lipitor than with Simvastatin: Pfizer
February 25, 2008
- One in 3 Physicians Recognizes Diovan Advertisements
February 25, 2008
- Meeting Market Needs with Original Drugs and Generics: Mochida
February 25, 2008
- Mevalotin Reduces Risk of CV Events in Postmenopausal Women
February 25, 2008
- FUJIFILM Embarks on Drug Business in Earnest by Acquiring Toyama Chemical
February 25, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…